Abstract
P008 Pharmacokinetics and pharmacodynamics in cynomolgus monkeys of AMG 181, a fully human anti a4 b7 antibody for treating inflammatory bowel disease W.-J. Pan1 *, S. Lear2, S. Patel1, P. Prince1, D. Doherty1, C.-Y. Tam1, C. Sheckler1, H. Hsu3, W. Rees2, A. Anderson4, J. Wisler5, K. Reynhardt6, J. Lynch7, J. Brandvig8, L. Wienkers1, D. Borie9. 1Amgen Inc., Pharmacokinetics and Drug Metabolism, Seattle, United States, 2Amgen Inc., Molecular Sciences and Computational Biology, Seattle, United States, 3Amgen Inc., Inflammation, Thousand Oaks, United States, 4Amgen Inc., Molecular Sciences and Computational Biology, Thousand Oaks, United States, 5Amgen Inc., Toxicology, Thousand Oaks, United States, 6Amgen Inc., Clinical Immunology, Seattle, United States, 7Charles River Laboratories, Preclinical Services, Reno, United States, 8Amgen Inc., Toxicology, Seattle, United States, 9Amgen Inc., Inflammation Clinical Research, Thousand Oaks, United States
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
